GlassScriptPhysician profile
Muhammad M Mirza
NPI 1467670984
$11,903.36
in general payments reported to CMS, 2019-2025
65 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,481 · 2020: $335 · 2021: $291 · 2022: $2,020 · 2023: $2,830 · 2024: $2,570 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,523 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,522.71 |
| Education | $253.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,002.24 | 2019-2025 | |
| Pfizer INC. | $980.89 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $915.08 | 2019-2025 | Keytruda, Reblozyl, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $857.95 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $628.97 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Gilead Sciences, INC. | $597.72 | 2022-2025 | Trodelvy |
| Amgen INC. | $492.45 | 2019-2023 | Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $478.51 | 2019-2025 | Ninlaro, Iclusig |
| Glaxosmithkline, LLC. | $478.46 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $427.81 | 2019-2025 | |
| Janssen Biotech, INC. | $358.94 | 2019-2025 | Rybrevant, Akeega, Balversa |
| Genentech USA, INC. | $325.91 | 2019-2025 | Phesgo, Tecentriq, Perjeta |
| Lilly USA, LLC | $316.46 | 2019-2025 | Jaypirca, Verzenio |
| Incyte Corporation | $308.68 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $278.22 | 2022-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $275.57 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Seagen INC. | $258.27 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Astellas Pharma US INC | $227.35 | 2022-2025 | Vyloy, Xtandi, Padcev |
| Puma Biotechnology, INC. | $175.50 | 2019-2023 | |
| Daiichi Sankyo INC. | $138.91 | 2019-2025 | Enhertu, Injectafer |
| Mirati Therapeutics, INC. | $125.96 | 2023-2024 | Krazati |
| Emd Serono, INC. | $119.65 | 2023-2025 | Bavencio, Tepmetko |
| Tersera Therapeutics LLC | $115.24 | 2023-2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $114.07 | 2022-2025 | Libtayo |
| Genzyme Corporation | $113.49 | 2019-2024 | |
| Tempus Ai, INC | $109.71 | 2024-2025 | Xt Cdx |
| Alexion Pharmaceuticals, INC. | $105.95 | 2022-2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $101.26 | 2019-2025 | |
| Exelixis INC. | $99.50 | 2022-2025 | Cabometyx |
| Taiho Oncology, INC. | $86.37 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $80.99 | 2022-2023 | Xarelto |
| Adaptive Biotechnologies Corporation | $80.46 | 2023-2024 | Clonoseq |
| Kite Pharma, INC. | $67.80 | 2023-2025 | Yescarta |
| Servier Pharmaceuticals LLC | $65.57 | 2023-2025 | |
| Blueprint Medicines Corporation | $64.66 | 2023-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.45 | 2021-2023 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $55.34 | 2022-2024 | Rezlidhia, Tavalisse |
| Beigene USA, INC. | $50.69 | 2024-2025 | Brukinsa |
| Geron Corporation | $47.43 | 2025 | Rytelo |
| Morphosys, US INC. | $45.87 | 2022-2023 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $45.48 | 2024 | Cosela, Monoferric |
| Jazz Pharmaceuticals INC. | $42.29 | 2023-2025 | |
| Kyowa Kirin, INC. | $40.77 | 2019-2022 | |
| Beone Medicines USA, INC. | $39.78 | 2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $38.70 | 2022-2023 | Qinlock |
| Sobi, INC | $36.60 | 2022 | |
| Aveo Pharmaceuticals, INC. | $34.36 | 2023-2025 | Fotivda |
| Apellis Pharmaceuticals, INC. | $33.29 | 2023 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $33.08 | 2022-2023 | Imbruvica |
| G1 Therapeutics, INC. | $29.55 | 2022 | |
| Sumitomo Pharma America, INC. | $27.87 | 2023 | Orgovyx |
| Recordati_rare_diseases_inc. | $27.52 | 2025 | Enjaymo |
| Coherus Oncology, INC. | $26.24 | 2022 | |
| Pharmaessentia USA Corporation | $24.68 | 2023 | Besremi |
| Genmab U.S., INC. | $22.69 | 2025 | Epkinly |
| Legend Biotech USA INC. | $21.74 | 2024 | |
| Syndax Pharmaceuticals, INC. | $21.14 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.79 | 2022 | |
| Biocompatibles, INC. | $19.70 | 2019 | |
| Acrotech Biopharma INC. | $17.88 | 2025 | Beleodaq |
| Karyopharm Therapeutics INC. | $17.19 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.55 | 2019 | |
| Cti Biopharma Corp. | $14.24 | 2023 | Vonjo |
| Ultragenyx Pharmaceutical INC. | $13.33 | 2023 | |
| Verastem, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Mirza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.